Oops! This Content is Members Only

Recent Content

• Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma
• Real-life experience with plasmapheresis in newly diagnosed multiple myeloma accompanied by acute kidney injury
• Health care professionals express support for postpartum depression, myeloma treatments
• Physical Activity Improves Performance, Frailty Scores, and PROs in Multiple Myeloma
• Limited Efficacy Seen With Ixazomib Plus Daratumumab and Low-Dose Dexamethasone in Intermediate-Fit Patients With MM
• Dr Beksac on OS Data From the OPTIMISMM Trial in Relapsed/Refractory Multiple Myeloma
• Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
• A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
• Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
• Lenalidomide Promotes Thrombosis Formation, but Does Not Affect Platelet Activation in Multiple Myeloma